Key Takeaways
- TD Cowen upgraded UnitedHealth to Buy on Nov. 20 with a $455 target, 34% above the Nov. 20 close.
- Most of the stock’s drop came after CMS proposed clawing back Medicare Advantage overpayments as far back as 2018, a plan that hit Humana even harder on Nov. 18.
- UnitedHealth’s and Elevance Health’s third quarters both show the Medicare Advantage margin repair TD Cowen is counting on.
- At about 17x 2028 earnings, below the stock’s five-year average of 19x, $455 looks conservative as long as the audit rule leaves 2028 earnings intact.
On Nov. 20, TD Cowen’s Ryan Langston upgraded UnitedHealth Group (UNH) to Buy from Hold, raised his target to $455 from $402, and named it the firm’s best idea for 2027. The stock rose 2.84% that day to $339.85, still 22% below its July 21 closing high of $436.35, which leaves 34% upside to the new target.
Washington’s audit plan hit Humana (HUM) even harder: it fell 12.7% on Nov. 18. And Elevance Health (ELV) is showing the same margin repair TD Cowen is counting on.
Washington Is UnitedHealth’s Problem
CMS proposed its CRUSH rule on Nov. 16. UnitedHealth’s selloff began the next trading day, when the stock fell 5.42% to $389.68. The rule would extrapolate Medicare Advantage audit findings from sampled charts to whole contracts and claw back overpayments as far back as 2018. CMS puts the industry’s recoveries at about $9 billion per payment year, and UnitedHealth hasn’t sized its share.
Sen. Elizabeth Warren, whose party has just won control of Congress, also called for breaking up UnitedHealth, CVS Health and Cigna, saying they “take a cut at every step.” UnitedHealth fell 10.2% on Nov. 18, and Humana, which has even more to lose from the audits, lost 12.7%.
TIKR Tracks 26 Analysts on UnitedHealth. How Many Say “Buy”?
See the full breakdown of Buy, Hold, and Sell ratings on UnitedHealth, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. See UnitedHealth’s Analyst Ratings
TD Cowen Is Looking at the Earnings
TD Cowen sees a “credible path” to earnings growth in the mid-to-high teens a year through at least 2028, from Medicare Advantage benefit design, Optum Health’s recovery and better commercial results.
The repair is already in the numbers. UnitedHealth’s third-quarter adjusted EPS rose to $4.69 from $2.92 as the medical care ratio fell to 88.4% from 89.9%, and it would have been 89.1% even without $610 million of favorable reserve development. Elevance’s benefit expense ratio improved 70 basis points to 90.6%, on better Medicare Advantage and individual ACA results.
Does $455 Add Up for UnitedHealth Stock?
The average analyst target is $476, up from $386 a year ago:

Analysts expect $23.33 of adjusted EPS for 2027 and $27.28 in 2028, almost back to 2024’s $27.66:

TD Cowen’s $455 is about 17x the Street’s 2028 estimate. UnitedHealth trades at about 15x forward earnings now, against a five-year average of 19x:

So most of the upside is earnings growth, plus a smaller step up in a multiple that stays below its average.
Cheap, With One Big Catch
Oppenheimer expects recoveries to be concentrated in 2028 through 2030. How much the audits could reduce UnitedHealth’s 2028 adjusted EPS remains unclear. Even so, TD Cowen’s $455 looks conservative to me, since it asks for less than UnitedHealth’s usual multiple on earnings still below 2024’s. The 2027 outlook, due before year-end, is the next test: a guide at or above the $23.33 analysts expect keeps the 2028 math on track. CMS’s comment period on the rule closes Jan. 19, 2027.
So What Is UnitedHealth Stock Actually Worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what UnitedHealth could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!